Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRx0518 and Avelumab Maintenance in Urothelial Carcinoma
NCT05107427Phase 2Withdrawn
- Sponsor
- 4D Pharma plc
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRx0518 in urothelial carcinoma (UC), sponsored by 4D Pharma plc. Primary endpoints: Safety of MRx0518 and Avelumab combination treatment and Landmark Progression-Free Survival at 6 months. Planned start Mar 2022; status: withdrawn.
02
Drugs
MRx0518
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05107427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107427.